Glycan Pharmaceuticals Inc., Repligen deal

Rusche was the scientific manager of RGEN's 60.1 program. RGEN has Phase II data on the small molecule for inflammatory disorders, which was under co-development with Eli Lilly and Co. until mid-1995, when the pharma company reprioritized its R&D programs. RGEN also has a chemokine program in early research.

Glycan, which also sells screening assays, has a screening collaboration with Glaxo and another undisclosed pharmaceutical partner. Herlihy said the company was at about breakeven in 1995 on revenues of $1 million. ...